Plasma exchange and intravenous immunoglobulin for the peri‐operative management of type 2 heparin‐induced thrombocytopaenia in a patient requiring urgent surgery for critical limb ischaemia

Summary: We report the case of a 61‐year‐old female who developed heparin‐induced thrombocytopaenia following treatment of a submassive pulmonary embolism, and who then required an above knee amputation for critical limb ischaemia. Heparin‐induced thrombocytopaenia is a rare, immune‐mediated complic...

Full description

Bibliographic Details
Main Authors: Perera, Y, Taylor, R, Bera, KD, Holman, L, Curry, N, Shah, A
Format: Journal article
Language:English
Published: Wiley Open Access 2024
_version_ 1811140017600331776
author Perera, Y
Taylor, R
Bera, KD
Holman, L
Curry, N
Shah, A
author_facet Perera, Y
Taylor, R
Bera, KD
Holman, L
Curry, N
Shah, A
author_sort Perera, Y
collection OXFORD
description Summary: We report the case of a 61‐year‐old female who developed heparin‐induced thrombocytopaenia following treatment of a submassive pulmonary embolism, and who then required an above knee amputation for critical limb ischaemia. Heparin‐induced thrombocytopaenia is a rare, immune‐mediated complication associated with an in‐hospital mortality rate of 10%. It is more common in surgical patients, with patients undergoing orthopaedic surgery more likely to develop it than patients undergoing cardiac surgery, but heparin‐dependent immunoglobulin G antibodies are more likely to be formed in the latter. Peri‐operative management remains a challenge. Ideally, it is preferable to wait for the platelet count to improve; but in certain cases, surgery cannot be delayed. Heparin‐induced thrombocytopaenia is usually managed with direct thrombin inhibitors, such as argatroban and bivalirudin. Newer therapeutic modalities, such as plasmapheresis and intravenous immunoglobulin, as used in this case, can rapidly remove antibodies, but the certainty of evidence is low. Our case adds to the literature regarding the use of these modalities and highlights the multidisciplinary team approach required to manage such complex cases.
first_indexed 2024-09-25T04:15:18Z
format Journal article
id oxford-uuid:4ccf346f-d9bb-4bf4-bfa9-de7a1cecb979
institution University of Oxford
language English
last_indexed 2024-09-25T04:15:18Z
publishDate 2024
publisher Wiley Open Access
record_format dspace
spelling oxford-uuid:4ccf346f-d9bb-4bf4-bfa9-de7a1cecb9792024-07-17T20:03:44ZPlasma exchange and intravenous immunoglobulin for the peri‐operative management of type 2 heparin‐induced thrombocytopaenia in a patient requiring urgent surgery for critical limb ischaemiaJournal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:4ccf346f-d9bb-4bf4-bfa9-de7a1cecb979EnglishJisc Publications RouterWiley Open Access2024Perera, YTaylor, RBera, KDHolman, LCurry, NShah, ASummary: We report the case of a 61‐year‐old female who developed heparin‐induced thrombocytopaenia following treatment of a submassive pulmonary embolism, and who then required an above knee amputation for critical limb ischaemia. Heparin‐induced thrombocytopaenia is a rare, immune‐mediated complication associated with an in‐hospital mortality rate of 10%. It is more common in surgical patients, with patients undergoing orthopaedic surgery more likely to develop it than patients undergoing cardiac surgery, but heparin‐dependent immunoglobulin G antibodies are more likely to be formed in the latter. Peri‐operative management remains a challenge. Ideally, it is preferable to wait for the platelet count to improve; but in certain cases, surgery cannot be delayed. Heparin‐induced thrombocytopaenia is usually managed with direct thrombin inhibitors, such as argatroban and bivalirudin. Newer therapeutic modalities, such as plasmapheresis and intravenous immunoglobulin, as used in this case, can rapidly remove antibodies, but the certainty of evidence is low. Our case adds to the literature regarding the use of these modalities and highlights the multidisciplinary team approach required to manage such complex cases.
spellingShingle Perera, Y
Taylor, R
Bera, KD
Holman, L
Curry, N
Shah, A
Plasma exchange and intravenous immunoglobulin for the peri‐operative management of type 2 heparin‐induced thrombocytopaenia in a patient requiring urgent surgery for critical limb ischaemia
title Plasma exchange and intravenous immunoglobulin for the peri‐operative management of type 2 heparin‐induced thrombocytopaenia in a patient requiring urgent surgery for critical limb ischaemia
title_full Plasma exchange and intravenous immunoglobulin for the peri‐operative management of type 2 heparin‐induced thrombocytopaenia in a patient requiring urgent surgery for critical limb ischaemia
title_fullStr Plasma exchange and intravenous immunoglobulin for the peri‐operative management of type 2 heparin‐induced thrombocytopaenia in a patient requiring urgent surgery for critical limb ischaemia
title_full_unstemmed Plasma exchange and intravenous immunoglobulin for the peri‐operative management of type 2 heparin‐induced thrombocytopaenia in a patient requiring urgent surgery for critical limb ischaemia
title_short Plasma exchange and intravenous immunoglobulin for the peri‐operative management of type 2 heparin‐induced thrombocytopaenia in a patient requiring urgent surgery for critical limb ischaemia
title_sort plasma exchange and intravenous immunoglobulin for the peri operative management of type 2 heparin induced thrombocytopaenia in a patient requiring urgent surgery for critical limb ischaemia
work_keys_str_mv AT pereray plasmaexchangeandintravenousimmunoglobulinfortheperioperativemanagementoftype2heparininducedthrombocytopaeniainapatientrequiringurgentsurgeryforcriticallimbischaemia
AT taylorr plasmaexchangeandintravenousimmunoglobulinfortheperioperativemanagementoftype2heparininducedthrombocytopaeniainapatientrequiringurgentsurgeryforcriticallimbischaemia
AT berakd plasmaexchangeandintravenousimmunoglobulinfortheperioperativemanagementoftype2heparininducedthrombocytopaeniainapatientrequiringurgentsurgeryforcriticallimbischaemia
AT holmanl plasmaexchangeandintravenousimmunoglobulinfortheperioperativemanagementoftype2heparininducedthrombocytopaeniainapatientrequiringurgentsurgeryforcriticallimbischaemia
AT curryn plasmaexchangeandintravenousimmunoglobulinfortheperioperativemanagementoftype2heparininducedthrombocytopaeniainapatientrequiringurgentsurgeryforcriticallimbischaemia
AT shaha plasmaexchangeandintravenousimmunoglobulinfortheperioperativemanagementoftype2heparininducedthrombocytopaeniainapatientrequiringurgentsurgeryforcriticallimbischaemia